Evaluating Silk Road Medical: Insights From 6 Financial Analysts

Ratings for Silk Road Medical SILK were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $20.83, with a high estimate of $24.00 and a low estimate of $18.00. Surpassing the previous average price target of $15.60, the current average has increased by 33.53%.

Decoding Analyst Ratings: A Detailed Look

The standing of Silk Road Medical among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Silk Road Medical. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Silk Road Medical compared to the broader market.
• Price Targets: Gaining insights, analysts provide estimates for the future value of Silk Road Medical's stock. This comparison reveals trends in analysts' expectations over time.

For valuable insights into Silk Road Medical's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on Silk Road Medical analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Discovering Silk Road Medical: A Closer Look

Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines novel endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy. The company generates all of its revenue in the United States.

Silk Road Medical: Delving into Financials

Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.

Revenue Growth: Silk Road Medical's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 17.97%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: Silk Road Medical's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -27.52%, the company may face hurdles in effective cost management.

Return on Equity (ROE): Silk Road Medical's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -8.55%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): Silk Road Medical's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -4.95%, the company may face hurdles in achieving optimal financial returns.

Debt Management: Silk Road Medical's debt-to-equity ratio is below the industry average at 0.51, reflecting a lower dependency on debt financing and a more conservative financial approach.

Analyst Ratings: What Are They?

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

This article was generated by Benzinga's automated content engine and reviewed by an editor.